School of Medicine, Xi'an Jiaotong University, Xi'an, 710061, P.R. China.
Eur J Med Chem. 2010 Jul;45(7):2798-805. doi: 10.1016/j.ejmech.2010.03.001. Epub 2010 Mar 7.
Antiangiogenic therapy might represent a new promising anticancer therapeutic strategy. Taspine can significantly inhibit cell proliferation of human umbilical vein endothelial cells (HUVECs) induced by vascular endothelial growth factor-165, which is crucial for angiogenesis. In this study, a series of novel taspine derivatives were synthesized and screened for in vitro anticancer and antiangiogenesis activities. The majority of the derivatives demonstrated a moderate degree of cytotoxicity against human cancer cell lines. One of them (14) exhibited much better antiproliferative activity against CACO-2 (IC(50)=52.5microM) and ECV304 (IC(50)=2.67microM) cells than taspine did. Some of them were also effective in antiproliferative assays against HUVECs. The in silico estimate of solubility of title compounds were higher than that of taspine.
抗血管生成治疗可能代表一种新的有前途的抗癌治疗策略。紫杉醇能够显著抑制血管内皮生长因子-165诱导的人脐静脉内皮细胞(HUVEC)的增殖,这对于血管生成至关重要。在这项研究中,合成了一系列新型紫杉醇衍生物,并对其进行了体外抗癌和抗血管生成活性的筛选。大多数衍生物对人癌细胞系具有中等程度的细胞毒性。其中之一(14)对 CACO-2(IC50=52.5μM)和 ECV304(IC50=2.67μM)细胞的增殖活性比紫杉醇强得多。它们中的一些在抑制 HUVEC 增殖的实验中也有效。标题化合物的溶解度的计算预测值均高于紫杉醇。